Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, discuss the role of PI3K inhibitor combination therapy and novel agents on the horizon for the treatment of R/R FL and MZL.
Video Programs
Advertisement
Stephen Oh, MD, PhD, discusses the nuances of identifying disease progression vs transformation in patients with essential thrombocythemia.
Advertisement
Experts in essential thrombocythemia review first line treatment options.
Ruben Mesa, MD, and panel discuss the role of molecular profile in treatment decision-making.
Experts in essential thrombocythemia discuss approaches to individualizing therapy.
Dr Stephen Oh discusses risk assessment in patients with essential thrombocythemia.
Advertisement
Stephen Oh, MD, PhD, reviews the case of a 46-year-old female with essential thrombocythemia.
Experts in hematology/oncology review data from the UNITY-NHL trial and share insights on the sequencing of therapies in R/R FL and MZL.
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review the tolerability and efficacy of umbralisib in the management of R/R FL and MZL.
Expert hematologist/oncologists comment on the safety profile of PI3K inhibitors when treating R/R FL and MZL and share their approach to managing associated adverse events.
Advertisement
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review clinical trial data for idelalisib, copanlisib, and duvelisib and discuss their personal experience using these agents for the management of R/R FL and MZL.
Looking ahead, Loretta Nastoupil, MD, reviews the future direction and unmet needs in the management of relapsed/refractory follicular lymphoma (R/R FL).
Dr Loretta Nastoupil describes best practices for managing the side effects of tazemetostat in patients with R/R FL.
Loretta Nastoupil, MD, discusses the use of tazemetostat in patients with and without an EZH2m.
Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.
Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.
A key opinion leader in the treatment of FL provides insight on the decision of whether to add maintenance therapy to the treatment regimen.
Loretta Nastoupil, MD, discusses first-line therapy options for patients with newly diagnosed follicular lymphoma (ND FL).
Loretta Nastoupil, MD, describes the role of molecular testing used in risk stratification of patient with FL
Loretta Nastoupil, MD, reviews the case of a 75-year-old woman with relapsed/refractory follicular lymphoma (R/R FL).
Expert hematologist/oncologists discuss the use of early PI3K inhibitors in the management of R/R follicular lymphoma (FL) and MZL (marginal zone lymphoma).
Ian W. Flinn, MD, PhD, leads the discussion on the various PI3K isoforms and their role in lymphoma.
Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.
Experts in myelofibrosis present safety and efficacy data from a clinical trial of fedratinib in patients with high risk myelofibrosis.
Dr Jamile Shammo presents clinical trial data on the efficacy and safety of ruxolitinib in patients with high risk myelofibrosis.
Experts in MPN review data on predictors of response to ruxolitinib in high risk myelofibrosis.
Jamile Shammo, MD, reviews prognostic models in myelofibrosis.
Dr Jamile Shammo reviews the case of a 72-year-old man with primary myelofibrosis.
Experts in polycythemia vera review data regarding the role of symptomatic improvement in overall outcome in patients with polycythemia vera.
Prithviraj Bose, MD, and colleagues discuss treatment options for high risk polycythemia vera.